European Bank for Reconstruction and Development and EU support Tunisian generic pharmaceuticals manufacturer

June 22, 2020
Share on

An advisory project jointly supported by the European Bank for Reconstruction and Development (EBRD) and the European Union helped IPS, a pharmaceutical business in Tunisia, strengthen the management of its operations and secure a path towards sustainable growth.

At a critical juncture in its development, IPS set a goal for broadening the scope of its activities and entering the European market, but it hit a roadblock. A rudimentary production management model hampered the company’s ability to grow in a sustainable fashion. The overconsumption of raw materials and other inefficiencies were undermining profitability. Through the Advice for Small Businesses initiative, the EBRD and the EU assigned IPS a consultant who helped the manufacturer implement a new IT system to streamline operations and reduce the risk of errors.

In the wake of the coronavirus, small businesses around the EBRD’s countries of operations are pulling off impressive feats, stepping up their own operations to help in any way they can. In Tunisia, IPS has followed suit and, in collaboration with the Tunisian Association of Generic Drugs and two other laboratories, has donated essential drugs to Tunisia’s Ministry of Health.

In Tunisia, the EBRD helps small businesses strengthen their knowhow with expert advisory services funded under the EU Initiative for Financial Inclusion.


Read More

Press Release

European Bank for Reconstruction and Development (EBRD)

Countries covered:

  • Tunisia